Biodesix, Inc. BDSX
21.05 USD -0.73 (-3.35%)
At closeNov 3, 2026, 4:00 PM EST
21.05 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
20.74 Day range 22.89
5.26 52-week range 31.97
- YTD
- +209.56%
- 1 year
- +232.02%
Analyst view
Price target (mean) 3.10 -85.3% downside
Now 21.05
- Target (low)
- 3.00
- Target (mean)
- 3.10
- Target (high)
- 3.50
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 19.83M | +35.2% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 20.22M | +36.5% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 70.73M | +44.1% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 92.25M | +30.4% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2024 | Scotiabank | Initiated | — | Sector Outperform |
| Jul 26, 2024 | Craig-Hallum | Initiated | — | Buy |
| May 13, 2024 | TD Cowen | Initiated | — | Buy |
| May 3, 2024 | Lake Street | Initiated | — | Buy |
| Mar 4, 2024 | Canaccord Genuity | Reiterated | Buy | Buy |
| Dec 7, 2023 | Canaccord Genuity | Reiterated | Buy | Buy |
| May 12, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Apr 20, 2022 | Cowen & Co. | Initiated | — | Outperform |
| Nov 17, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| May 12, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Mar 18, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Feb 2, 2021 | Canaccord Genuity | Maintained | — | Buy |
| Nov 23, 2020 | William Blair | Initiated | — | Outperform |
| Nov 23, 2020 | BTIG | Initiated | — | Buy |
| Nov 23, 2020 | Morgan Stanley | Initiated | — | Overweight |